Cimitan M, Volpe R, Candiani E, Gusso G, Ruffo R, Borsatti E, Massarut S, Rossi C, Morassut S, Carbone A
Department of Nuclear Medicine and Diagnostic Ultrasound, Centro di Riferimento Oncologico-IRCCS, Aviano, Italy.
Eur J Nucl Med. 1995 Oct;22(10):1110-7. doi: 10.1007/BF00800591.
Thallium-201 breast scans were performed preoperatively in 72 female patients with breast abnormalities detected by mammography and/or ultrasonography (7.5-13 MHz), in order to differentiate benign from malignant breast disease. Informed consent was obtained from each patient. Scintigraphy consisted of anterior and oblique planar images of the affected breast and axilla at 10 min and 3 h following the injection of 201Tl chloride (110 MBq). All 201Tl scans were interpreted without prior knowledge of surgery data. Pathological features of breast malignancies, such as tumour size, axillary lymph node metastases, tumour grading, lymphatic vascular channel invasion and receptor status, were analysed for their association with 201Tl uptake by tumour cells. A total of 76 breast lesions were assessed in the study. On final histological diagnosis, there were 56 malignant tumours, 14 benign nodules (9 fibroadenomas, two cases of adenosis, two cases of focal fibrosis and one case of epitheliosis) and six atypical lesions (atypical ductal or lobular hyperplasia). Thallium scintigraphy was shown to have high accuracy (92%) in detecting breast cancer, better than mammography (74%) and ultrasonography (84%). Almost all (51/56) breast cancers showed greater 201Tl activity than surrounding normal breast tissue while there was no significant increase in 201Tl activity above background in all but one (19/20) case of non-malignant disease. 201Tl activity within breast tumours, calculated as tumour/background (T/B) ratio, ranged between 1.2 and 2.5 with a mean value of 1.45. In our experience the concentration of thallium in the breast cancer seems to be primarily dependent on vascularity and tumour size rather than tumour grading, lymphatic/vascular invasion or receptor status. 201Tl scan sensitivity was 97% for malignant lesions larger than 1.5 cm (n = 35) and 80% for lesions of 1.5 cm or less (n = 21); however, five of the eight breast cancers smaller than 1.0 cm were also detectable by 201Tl scintigraphy, compared with five out of seven by mammography. Thallium scintigraphy would not be useful in evaluating the axilla for lymph node metastases (sensitivity 27%, specificity 77%).
对72例经乳腺X线摄影和/或超声检查(7.5 - 13MHz)发现乳腺异常的女性患者进行了术前铊-201乳腺扫描,以鉴别乳腺良性疾病与恶性疾病。每位患者均签署了知情同意书。闪烁扫描包括在注射氯化铊-201(110MBq)后10分钟和3小时对患侧乳腺及腋窝进行前后位和斜位平面显像。所有铊-201扫描均在不了解手术数据的情况下进行解读。分析乳腺恶性肿瘤的病理特征,如肿瘤大小、腋窝淋巴结转移、肿瘤分级、淋巴管侵犯及受体状态,以探讨其与肿瘤细胞摄取铊-201的相关性。本研究共评估了76个乳腺病变。最终组织学诊断显示,有56个恶性肿瘤、14个良性结节(9个纤维腺瘤、2例腺病、2例局灶性纤维化和1例上皮组织增生)以及6个非典型病变(非典型导管或小叶增生)。铊闪烁扫描在检测乳腺癌方面具有较高的准确性(92%),优于乳腺X线摄影(74%)和超声检查(84%)。几乎所有(51/56)乳腺癌的铊-201活性均高于周围正常乳腺组织,而除1例(19/20)外,所有非恶性疾病的铊-201活性均未显著高于背景值。乳腺肿瘤内的铊-201活性以肿瘤/背景(T/B)比值计算,范围在1.2至2.5之间,平均值为1.45。根据我们的经验,乳腺癌中的铊浓度似乎主要取决于血管分布和肿瘤大小,而非肿瘤分级、淋巴管/血管侵犯或受体状态。对于大于1.5cm的恶性病变(n = 35),铊-201扫描的敏感性为97%;对于1.5cm或更小的病变(n = 21),敏感性为80%;然而,8个小于1.0cm的乳腺癌中有5个也可通过铊-201闪烁扫描检测到,而乳腺X线摄影在7个中只能检测到5个。铊闪烁扫描在评估腋窝淋巴结转移方面并无用处(敏感性27%,特异性77%)。